102 related articles for article (PubMed ID: 26296147)
1. Initial Experience With Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients With Refractory Metastatic Neuroblastoma.
Kong G; Hofman MS; Murray WK; Wilson S; Wood P; Downie P; Super L; Hogg A; Eu P; Hicks RJ
J Pediatr Hematol Oncol; 2016 Mar; 38(2):87-96. PubMed ID: 26296147
[TBL] [Abstract][Full Text] [Related]
2. PRRT with Lu-177 DOTATATE in Treatment-Refractory Progressive Meningioma: Initial Experience from a Tertiary-Care Neuro-Oncology Center.
Puranik AD; Dev ID; Rangarajan V; Kulkarni S; Shetty N; Gala K; Sahu A; Bhattacharya K; Dasgupta A; Chatterjee A; Gupta T; Sridhar E; Sahay A; Shetty P; Singh V; Moiyadi A; Menon N; Purandare NC; Agrawal A; Shah S; Choudhury S; Ghosh S; Jha AK
Neurol India; 2024 Mar; 72(2):278-284. PubMed ID: 38691470
[TBL] [Abstract][Full Text] [Related]
3. A Peptide Meets a Radionuclide to Combat a Rare Tumor.
Thomas KE; Boudreaux JP; Thiagarajan R; Marsala A; Voros BA; Ramirez RA
Ochsner J; 2021; 21(3):306-311. PubMed ID: 34566515
[No Abstract] [Full Text] [Related]
4. Review: The Role of Radiolabeled DOTA-Conjugated Peptides for Imaging and Treatment of Childhood Neuroblastoma.
Alexander N; Vali R; Ahmadzadehfar H; Shammas A; Baruchel S
Curr Radiopharm; 2018; 11(1):14-21. PubMed ID: 29243585
[TBL] [Abstract][Full Text] [Related]
5. Peptide receptor radionuclide therapy of neuroendocrine tumours.
Brabander T; Teunissen JJ; Van Eijck CH; Franssen GJ; Feelders RA; de Herder WW; Kwekkeboom DJ
Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):103-14. PubMed ID: 26971847
[TBL] [Abstract][Full Text] [Related]
6. A phase IIa trial of molecular radiotherapy with 177-lutetium DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma.
Gains JE; Moroz V; Aldridge MD; Wan S; Wheatley K; Laidler J; Peet C; Bomanji JB; Gaze MN
Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2348-2357. PubMed ID: 32157433
[TBL] [Abstract][Full Text] [Related]
7. 68Ga-DOTATATE and 123I-mIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: implications for molecular radiotherapy.
Gains JE; Aldridge MD; Mattoli MV; Bomanji JB; Biassoni L; Shankar A; Gaze MN
Nucl Med Commun; 2020 Nov; 41(11):1169-1177. PubMed ID: 32796449
[TBL] [Abstract][Full Text] [Related]
8. Pediatric applications of Dotatate: early diagnostic and therapeutic experience.
McElroy KM; Binkovitz LA; Trout AT; Czachowski MR; Seghers VJ; Lteif AN; States LJ
Pediatr Radiol; 2020 Jun; 50(7):882-897. PubMed ID: 32495176
[TBL] [Abstract][Full Text] [Related]
9. 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma.
Bleeker G; Tytgat GA; Adam JA; Caron HN; Kremer LC; Hooft L; van Dalen EC
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD009263. PubMed ID: 26417712
[TBL] [Abstract][Full Text] [Related]
10. Feasibility and Therapeutic Potential of Combined Peptide Receptor Radionuclide Therapy With Intensive Chemotherapy for Pediatric Patients With Relapsed or Refractory Metastatic Neuroblastoma.
Fathpour G; Jafari E; Hashemi A; Dadgar H; Shahriari M; Zareifar S; Jenabzade AR; Vali R; Ahmadzadehfar H; Assadi M
Clin Nucl Med; 2021 Jul; 46(7):540-548. PubMed ID: 33782280
[TBL] [Abstract][Full Text] [Related]
11. A review of pediatric neuroendocrine tumors, their detection, and treatment by radioisotopes.
Haddad T; Fard-Esfahani A; Vali R
Nucl Med Commun; 2021 Jan; 42(1):21-31. PubMed ID: 33044400
[TBL] [Abstract][Full Text] [Related]
12. EANM procedure guidelines for radionuclide therapy with
Kratochwil C; Fendler WP; Eiber M; Baum R; Bozkurt MF; Czernin J; Delgado Bolton RC; Ezziddin S; Forrer F; Hicks RJ; Hope TA; Kabasakal L; Konijnenberg M; Kopka K; Lassmann M; Mottaghy FM; Oyen W; Rahbar K; Schöder H; Virgolini I; Wester HJ; Bodei L; Fanti S; Haberkorn U; Herrmann K
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2536-2544. PubMed ID: 31440799
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical evaluation of molecular radiotherapy target expression in neuroblastoma tissue.
Gains JE; Sebire NJ; Moroz V; Wheatley K; Gaze MN
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):402-411. PubMed ID: 29043399
[TBL] [Abstract][Full Text] [Related]
14. A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of
Sundquist F; Georgantzi K; Jarvis KB; Brok J; Koskenvuo M; Rascon J; van Noesel M; Grybäck P; Nilsson J; Braat A; Sundin M; Wessman S; Herold N; Hjorth L; Kogner P; Granberg D; Gaze M; Stenman J
Front Pediatr; 2022; 10():836230. PubMed ID: 35359899
[TBL] [Abstract][Full Text] [Related]
15.
Maaz AUR; O'Doherty J; Djekidel M
J Nucl Med Technol; 2021 Sep; 49(3):265-268. PubMed ID: 33820858
[TBL] [Abstract][Full Text] [Related]
16. p53 stabilisation potentiates [
Berglund H; Salomonsson SL; Mohajershojai T; Gago FJF; Lane DP; Nestor M
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):768-778. PubMed ID: 37823909
[TBL] [Abstract][Full Text] [Related]
17. A genome-wide CRISPR/Cas9 screen identifies DNA-PK as a sensitiser to
Waldeck K; Van Zuylekom J; Cullinane C; Gulati T; Simpson KJ; Tothill RW; Blyth B; Hicks RJ
Theranostics; 2023; 13(14):4745-4761. PubMed ID: 37771787
[TBL] [Abstract][Full Text] [Related]
18. PET/CT Imaging in Treatment Planning and Surveillance of Sinonasal Neoplasms.
Akay S; Pollard JH; Saad Eddin A; Alatoum A; Kandemirli S; Gholamrezanezhad A; Menda Y; Graham MM; Shariftabrizi A
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568575
[TBL] [Abstract][Full Text] [Related]
19.
Rubira L; Deshayes E; Santoro L; Kotzki PO; Fersing C
Pharmaceutics; 2023 Mar; 15(4):. PubMed ID: 37111537
[TBL] [Abstract][Full Text] [Related]
20. SPECT/CT, PET/CT and PET/MRI: oncologic and infectious applications and protocol considerations.
Voss SD
Pediatr Radiol; 2023 Jun; 53(7):1443-1453. PubMed ID: 36899268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
